KRAS and pancreatic adenocarcinoma: Briefly, in accordance with the stage-specific influence of HLA-A02+B62+B44− on DFS in our cohort, its ‘indicator’ (co-mutant KRAS G12D and TP53) also had associations with poor survival of only early-stage but not late-stage PAAD patients in public cohorts.